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Introduction
Life expectancy has increased substantially over the past 
centuries. Along with the aging of the population, the inci-
dence of age-associated conditions increases and more 
attention and resources will be needed to manage these 
conditions. Osteoporosis, characterized by low bone min-
eral density (BMD) and microarchitectural deterioration 
of bone tissue associated with bone fragility and fracture 
risk, is of particular concern because of the major burden 
of osteoporotic fractures in terms of morbidity and mortal-
ity. BMD is not the sole criterion to determine fracture risk. 
An overall fracture risk assessment that combines multiple 
risk factors such as the WHO FRAX algorithm provides a 
more accurate evaluation.
Fracture probability estimated with the FRAX algorithm 
is, however, underestimated in patients with certain con-
ditions. For example, in the FRAX algorithm, anticancer 
treatment is not considered as a specific risk factor nor does 
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this algorithm include a “renal” parameter or a measure of 
sarcopenia and fall risk. Therefore, fracture risk in patients 
on some anticancer treatments, dialysis, or with severe kid-
ney disease or sarcopenia may be underestimated. Other 
risk factors such as age and low body mass index (BMI) 
are included in the FRAX algorithm. However, the algo-
rithm accepts only ages between 40 and 90 years, so not the 
very elderly and most of the patients with anorexia nervosa 
(AN), who, in general, are younger than 40 years. Also 
the management of osteoporosis in the oldest old and in 
patients with AN is of interest because currently approved 
therapies for osteoporosis have mainly been investigated in 
persons until the age of 75 years and are not indicated for 
use in young individuals.
Reducing fracture risk in frail individuals is of major 
importance because of the morbidity and mortality asso-
ciated with fragility fractures. In this consensus paper, we 
will review the current evidence about the evaluation and 
management of osteoporosis in frail persons, namely in 
patients with AN, patients on dialysis, cancer patients, per-
sons with sarcopenia, and the oldest old. Osteoporosis in 
other frail subsets of the population, such as in HIV posi-
tive patients and patients with diabetes mellitus, will not be 
discussed.
Osteoporosis in Patients with Anorexia Nervosa
The estimated lifetime prevalence of anorexia nervosa 
(AN) ranges between 0.6% and 4.2%, but these estimates 
are likely to be low due to the tendency of some individuals 
to conceal their illness [1]. AN is 10 times more common in 
women than men. In this section we will, therefore, discuss 
only women affected by AN and osteoporosis. The median 
age of onset of AN is 18 years [1]. The psychological pro-
file of young women with AN is that of women driven to 
excel, pressurized to fit a specific body image. Osteoporosis 
is common in AN. About half of these patients suffer from 
osteoporosis and almost all from osteopenia [2]. Although 
amenorrhea is not anymore required in the definition of 
AN, amenorrhea is common and the typical triade consists 
of low energy intake (generally related to eating disorders), 
osteoporosis, and amenorrhea.
Etiology
AN is associated with marked endocrine changes 
that also impair healthy bone turnover. As mentioned 
before, amenorrhea is common. In adolescents with AN, 
menarche is often delayed, contributing to low BMD. 
However, the severity of bone loss in women with AN 
is greater than in those with normal-weight hypotha-
lamic amenorrhea, indicating that, in addition to estradiol 
deficiency, there are other factors including nutritional 
deficiencies and hormonal abnormalities that contribute 
to bone loss. GH resistance, low levels of IGF-1, hyper-
cortisolemia, and low levels of testosterone have all been 
implicated in AN-associated osteopenia and osteoporosis. 
Abnormalities in hormones regulating appetite (oxytocin, 
leptin, and peptide tyrosine tyrosine (PYY)) may play an 
additional role [1]. Therefore, the etiology of bone loss in 
patients with AN is multifactorial.
Biological Markers of Bone Turnover
Klibanski et al. observed an uncoupling of bone turnover 
in adults with AN, with a decrease in markers of bone 
formation and an increase in markers of bone resorption. 
However, in adolescents with AN, there is a low bone 
turnover state with a decrease in the levels of bone for-
mation and resorption, as opposed to an increased bone 
turnover during normal adolescence [3]. Veronese et  al. 
conducted a meta-analysis of vitamin D status in AN 
patients [4]. They identified 15 studies (totalizing 927 
participants; AN = 408 and healthy controls = 519) and 
observed that, although AN patients reported similar 
dietary vitamin D intake compared to healthy controls, 
AN patients had significantly lower levels of 25OHD and 
1,25(OH)2D when not using vitamin D supplementation. 
Conversely, supplementation with cholecalciferol fully 
normalized serum levels of vitamin D [4].
Bone Loss and Fracture Risk
Both trabecular and cortical bone sites are affected in AN, 
but since there is a marked estrogen deficiency component 
in these women, trabecular osteoporosis (such as at the 
lumbar spine) is more frequent and prominent [5]. Based 
on HR-pQCT studies, it has been suggested that bone 
geometry, microarchitecture, marrow adiposity, as well as 
bone strength estimates are affected [5]. When AN affects 
women before reaching their peak bone mass, a reduced 
bone accrual will impeach them from attaining the optimal 
BMD, increasing their risk of fracture [6].
Not surprisingly, therefore, a two- to sevenfold increase 
in fractures has been reported in patients with AN [7, 
8]. Rigotti et  al. followed a series of 27 women with AN 
for a median of 25 months and concluded that anorectic 
women have an increased risk of fracture (RR 7.1; 95% CI 
3.2–18.5) and that BMD reductions appear not to be rap-
idly reversed by recovery from AN [7]. Vestergaard et al., 
using a case-control Danish Nationwide register study, also 
observed an increased fracture risk in AN, which persisted 
more than 10 years after the diagnosis [8].
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Assessment and Management of Osteoporosis in AN
The clinical assessment involves an osteoporosis assess-
ment consisting of BMD measurement and assessment of 
other risk factors for osteoporosis such as a personal history 
of low-trauma fractures, a family history of osteoporotic 
fractures, lifestyle factors, medication, and serum level of 
25OHD. In addition, checking for reproductive dysfunction 
(amenorrhea, follicle-stimulating hormone (FSH), lutein-
izing hormone (LH), estradiol) and measuring prolactin, 
thyroid-stimulating hormone (TSH), and human chorionic 
gonadotropin (hCG) is needed to rule out causes of amen-
orrhea other than AN.
Table  1 gives an overview of the management of low 
bone density in patients with AN. AN patients need to be 
encouraged to gain weight. Recovering a near-normal or 
normal BMI (18–25 kg/m2) will generally help to recover 
a normal reproductive functioning, which can be assessed 
by a regular menstrual cycle (not using hormone ther-
apy). Restoration of body weight will also improve BMD 
although a complete catch-up does not always occur [5]. In 
addition, AN patients should take adequate calcium (e.g., 
1200 mg) and vitamin D (e.g., 800 IU) daily, from diet and 
supplements.
High-dose estrogen–progestin contraception is not an 
effective treatment option for AN-associated bone loss 
in adolescents or adults. Indeed, prospective trials have 
failed to show a benefit of combination estrogen–proges-
tin oral contraceptives in treating AN-associated bone loss 
in adolescents or adults, although one may be tempted to 
restore menstruation in these patients using oral contracep-
tives. Unfortunately, several studies have failed to observe 
a protective effect of the “pill” containing 50 µg ethynile-
stradiol [11]. On the other hand, lower-dose physiologic 
estrogen replacement using MHT such as 100 µg transder-
mal 17-beta-estradiol with cyclic micronized progesterone 
in adolescents resulted in BMD gains at the spine and hip 
compared with placebo, though the therapy did not restore 
BMD to normal [10]. Although AN patients are also defi-
cient in androgens, androgen replacement is currently not 
recommended.
Limited data suggest that bisphosphonates may be 
of benefit in women with AN-associated bone loss. For 
instance, risedronate for 1 year resulted in a modest gain 
in BMD compared with placebo [13]. Another study, how-
ever, failed to report an improvement using alendronate vs. 
placebo [14]. Furthermore, there are safety concerns with 
bisphosphonates especially in younger patients who may 
want to become pregnant. Indeed, animal studies have sug-
gested placental transfer of bisphosphonates and fetal skel-
etal development involvement, and in a small series of 10 
women treated with bisphosphonates during pregnancy, 
Table 1  Management of low bone density in AN
*Few series
Adolescent girls Postmenopausal women
Lifestyle advise  Decrease exercise and increase weight gain
 Calcium and vitamin D
Decrease exercise and increase weight gain
Calcium and vitamin D
When to initiate pharmacological therapy?
 FRAX (FRAX is not intended for use in persons < 40 
years)
No specific guidelines for adults with AN
 DXA Z-score ≤ −2+ decreasing over time despite all 
efforts at weight gain [5, 9]
No specific guidelines for adults with AN
Which pharmacological therapy?
 Recommended  Lower-dose physiologic estrogen [10]
MHT (100 µg transdermal 17-beta-estradiol 
with cyclic micronized progesterone)
In adults with osteoporosis
 MHT (100 µg transdermal 17-beta-estradiol with 
cyclic micronized progesterone) in women aged
50–60 years*
 Bisphosphonates*
 Denosumab*
(schemes & doses for postmenopausal osteopo-
rosis)
 Not recommended  High-dose estrogen (oral contraception) [11] 
(“pill” containing 50 µg ethynilestradiol)
 Androgen replacement [5]
 Recombinant human insulin-like growth factor 
1
(rhIGF-1) (under investigation) [5]
 Bisphosphonates
 Denosumab
 Teriparatide
In adults with AN-associated bone loss
 Additional research is needed to confirm efficacy 
and safety of bisphosphonates [12]
 No data regarding use of Denosumab [5]
 Role for Teriparatide not yet clear (under investi-
gation) [5, 12]
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congenital malformations were reported in 20% [15]. 
Although most other data in literature suggest that precon-
ceptional and first-trimester use of bisphosphonates do not 
pose substantial fetal risks, it is recommended that, when 
bisphosphonates are prescribed to females of reproduc-
tive age, one should ensure that the patient is and will not 
become pregnant when using bisphosphonates [15]. Bis-
phosphonates are generally not approved for this indica-
tion, but may be used in elderly with AN. Also denosumab 
and teriparatide should not be used as first-line therapies in 
young patients suffering from AN-induced osteoporosis.
Conclusion
AN predominantly affects women at a young age. As a 
result, almost all endocrine axes are disturbed. This will 
lead to osteoporosis in about half of the patients and to 
osteopenia in almost all of them. The burden due to frac-
tures is important. A multidisciplinary management is 
needed, involving a gynecologist, endocrinologist, pedia-
trician (depending of the patients’ age), psychologist, 
nutritionist, and bone specialist. BMD measurement and 
an endocrine evaluation are mandatory. Other pathologies 
associated with weight loss, amenorrhea, and bone loss 
should be excluded. The ultimate therapy implies body 
weight restoration and regular cycle recovery. A healthy 
lifestyle is therefore mandatory. Calcium and vitamin D 
supplementation is recommended in all patients with AN. 
MHT is indicated in adolescent girls with sustained low 
weight, low BMD, and amenorrhea when other causes of 
amenorrhea have been excluded. Bisphosphonates and 
denosumab may be useful in adult women with severe bone 
loss.
Osteoporosis in Dialysis Patients
Fracture Risk in Dialysis Patients
Dialysis status is associated with an outstanding risk of 
fracture compared to the general population. In 2006, 
results from the international observational cohort DOPPS 
(Dialysis Outcomes and Practice Patterns Study) were pub-
lished. Such as in the general population, the risk of hip 
fracture in the dialysis population was higher in women and 
increased progressively with age, but, in both genders and 
in all age categories, the incidence of hip fracture was much 
higher in dialysis patients. For example, the incidence of 
fracture in women between 75 and 84 years was 1190 and 
3136 per 100,000 patients in the general and dialysis popu-
lation, respectively [16]. Similar data from USRDS (United 
States Renal Data System) showed a fourfold higher risk 
of fracture in dialysis compared to the general population 
[17]. There is also evidence that these fractures occur ear-
lier in life, and fractures in hemodialysis are associated 
with higher morbidity and even mortality. A mortality 
rate as high as 64% in the year following a hip fracture has 
been described in dialysis patients [18]. Of course, the risk 
of fracture is also tightly associated with the high risk of 
falls in this population, which is enhanced by factors such 
as older age, diabetes, depression, antidepressants, previous 
falls, malnutrition, and frailty.
Osteoporosis in Dialysis Patients: Bone Mass Versus 
Bone Turnover
In clinical practice, bone fragility is evaluated by DXA that 
measures both cortical and trabecular bone quantity. New 
CT-scan techniques (quantitative computed tomography 
(QCT) or high-resolution peripheral QCT (HR-pQCT)) 
are now available and currently used in clinical research 
with the main advantage of being able to separate corti-
cal and trabecular areas [19–21]. However, bone quantity 
is only one piece of the puzzle. Indeed, bone strength, and 
thus fracture risk, is dependent not only on bone quantity 
but also on bone quality which is determined by both bone 
turnover and mineralization, concepts being assessed by 
bone biopsy and histomorphometry [19, 22].
Bone disorders have been described for more than a 
century in chronic kidney disease (CKD) patients [22]. In 
2006, the international KDIGO (Kidney Disease: Improv-
ing Global Outcomes) guidelines proposed a common ter-
minology using the term “Chronic Kidney Disease-Mineral 
and Bone Disorder” (CKD-MBD) to encompass all pos-
sible abnormalities associated with bone disease and min-
eral disturbances [23]. CKD and still more dialysis status 
is associated with severe mineral abnormalities, such as 
hypocalcemia, hyperphosphatemia, and secondary hyper- 
or hypoparathyrodism. It is beyond the scope of this article 
to review the pathophysiology of such abnormalities [23, 
24] but basically they will be associated with either low 
(“adynamic bone disease”) or high (“osteitis fibrosa”) bone 
turnover disease in dialysis patients [22]. The vast majority 
of basic and clinical research in nephrology is thus focused 
on turnover abnormalities, and by consequence more on 
bone quality (turnover) than on bone quantity (osteoporo-
sis) [19]. Briefly, both low and high turnover seems associ-
ated with an increase of fracture risk [19–21, 23, 25]. Sensu 
stricto, such a diagnosis requires a bone biopsy but this 
technique remains relatively invasive, costly, and difficult to 
interpret and repeat. An important part of clinical research 
is thus about the role of biomarkers to estimate bone turno-
ver [24]. Currently, the KDIGO recommends the measure-
ment (and monitoring) of both parathyroid hormone (PTH) 
and bone-specific alkaline phosphatase (b-ALP), even if, 
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as discussed later in this chapter, the interpretation of the 
results remains frequently difficult and sometimes disap-
pointing [24].
Diagnosis of Osteoporosis in Dialysis Patients: DXA, 
FRAX and Biomarkers
Data on the utility of DXA in dialysis patients, notably for 
predicting the risk of fracture, are scarce and controversial 
in comparison to the literature in the general population. 
For this reason, but also because specific therapies for oste-
oporosis are not routinely used in dialysis, the KDIGO did 
not recommend routine DXA in dialysis patients when first 
published in 2009 [23]. This recommendation could, how-
ever, change in the next KDIGO recommendations. Indeed, 
a meta-analysis, including 6 studies and 683 (357 women) 
dialysis patients, suggested that low BMD was associated 
with fractures and this was true for all sites, except the fem-
oral neck [26]. However, data were heterogeneous and only 
cross-sectional. A longitudinal observational study in 485 
hemodialysis patients showed that DXA, especially at the 
hip region, was useful to predict incident fractures but only 
in patients with low PTH [25]. Beyond fracture risk, some 
authors suggested that in dialysis patients, osteoporosis and 
osteopenia were associated with an independent higher risk 
of mortality [27]. These data could lead to a broader use 
of DXA in dialysis patients in the future, even if currently 
the level of evidence is still relatively low. Therefore, at this 
time, a T-score threshold at which intervention should be 
started, cannot be recommended. Moreover, there are some 
specific technologic issues in dialysis patients. Indeed, 
these patients frequently suffer from spinal osteophytes and 
high vascular calcifications in the aorta making the inter-
pretation of DXA results at the lumbar region questionable, 
with a risk of spuriously good results [19, 27]. It is thus 
suggested to measure BMD in the radius region, especially 
when there is secondary hyperparathyroidism, and this is 
another reason why QCT and HR-pQCT are of potential 
interest in dialysis patients [20].
FRAX does not include any “renal” parameter. This 
score has not been validated in dialysis patients and is 
thus considered neither in the KDIGO nor in clinical prac-
tice. Therefore, 10-year FRAX risks at which intervention 
should be initiated cannot be recommended.
If the available literature on bone biomarkers to detect 
and/or monitor bone turnover abnormalities in dialysis 
patients is abundant [24], current data on these biomarkers 
to detect and/or monitor osteoporosis are scarce and con-
troversial. In the general population, biomarkers (especially 
β C-terminal cross-linked telopeptide (β-CTX) and N-ter-
minal propeptide of type I procollagen (PINP)) may be 
used to monitor the response to osteoporosis therapy [28]. 
This is, however, not relevant in dialysis patients as nearly 
all osteoporotic treatments are not recommended in these 
patients. The current knowledge on the ability of such bio-
markers to detect osteoporosis and/or to monitor bone loss 
is thus limited and controversial [21, 23]. A recent observa-
tional longitudinal study in 81 US dialysis patients meas-
ured several biomarkers as well as BMD by DXA and QCT 
at baseline and after one-year of follow-up [29]. At base-
line and after multivariate analysis with age, gender, BMI, 
and ethnicity as covariates, an association was observed 
between DXA at the hip and baseline PTH and b-ALP 
(negative association) and sclerostin (positive association). 
At the spine, the associations were significant with PTH 
and sclerostin but also with FGF-23. Considering change 
in BMD over a one-year period, there was no association 
between change in BMD at the hip and any biomarker. At 
the spine, change in BMD was, however, associated with 
baseline FGF-23 values (negative association) and with 
change in sclerostin (positive association). The associations 
observed between change in BMD measured by QCT and 
biomarkers are also significant but with other biomarkers 
than those associated with DXA (for example, tartrate-
resistant acid phosphatase-5b) and the associations are also 
different according to the region (hip or spine) [29]. The 
association between BMD or change in BMD and biomark-
ers are thus very heterogeneous, making the interpretation 
of this study difficult. Moreover, each biomarker, including 
“simple” biomarkers like PTH, has its own analytical and 
clinical limitations (accumulation in CKD, high intra-indi-
vidual variation, absence of normal reference values) [24]. 
Other studies on the same topic are thus urgently needed. 
For example, for PTH, second- and third-generation PTH 
assays are currently available, which measure 1–84 and 
7–84 PTH (‘intact’ PTH assay) and 1–84 PTH only, respec-
tively. KDIGO experts conclude that both the second- and 
the third-generation assays are similarly informative. How-
ever, the assays have high inter-method variability. There-
fore, KDIGO proposes to use a target range for serum PTH 
based on multiples of the upper limit of the normal values 
rather than on absolute concentrations [24].
Therapeutic Strategies in Dialysis Patients
The majority of therapeutic studies in dialysis patients 
focused on bone turnover abnormalities with, for exam-
ple, vitamin D or calcimimetics, although the majority of 
these studies used biomarkers, and not bone biopsies, as 
endpoint [19]. Clinical studies reporting fractures as hard 
clinical endpoint are even more scarce. One large RCT sug-
gests that fractures could be reduced in dialysis patients 
with hyperparathyroidism when treated with calcimimetics 
[30]. This was, however, a post hoc analysis with statistical 
adjustments, while the primary study was negative for the 
fracture endpoint [31].
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There are few studies about specific osteoporosis thera-
pies in dialysis patients as dialysis status was an exclu-
sion criterion in all large interventional trials on this topic 
[19–21]. The role of bisphosphonates in dialysis patients 
is still a subject of debate. Data in literature are scarce in 
severe CKD non-dialysis patients and even more limited in 
dialysis patients [20]. Some publications, however, suggest 
positive results on BMD [32]. Because 50% of the adminis-
tered dose of bisphosphonates gets excreted by the kidneys, 
the dosage used in these studies is lower than in the gen-
eral population. Limitations of these studies are the design, 
sample size, and follow-up (6–12 months). In theory, bis-
phosphonates are contraindicated in patients with low bone 
turnover. For this reason, the KDIGO recommends to per-
form a bone biopsy before a potential treatment with bis-
phosphonates. Also raloxifene has been hardly studied in 
dialysis patients. The safety profile seems acceptable in 
postmenopausal women on hemodialysis, but long-term 
data are lacking. The beneficial impact on BMD has been 
suggested by some prospective and sometimes randomized 
studies but the sample sizes and follow-up times were 
always limited (at best 26 patients in the treated group and 
follow-up of 1 year) [33]. Likewise, there are few clinical 
data on the benefit of strontium ranelate in dialysis patients 
and some authors have underlined the risk of osteoma-
lacia with this treatment in dialysis patients [34]. Recent 
osteoporosis therapies have theoretical interest in dialysis 
patients. Denosumab has been shown to be effective in 
dialysis patients but the numbers of included patients were 
low and all studies were open-label and non-randomized. 
Moreover, dialysis patients are at higher risk of develop-
ing severe hypocalcemia with denosumab [35]. Accord-
ing to some authors, this antiresorptive therapy should 
also be avoided in dialysis patients with low bone turnover 
[20]. Teriparatide and other PTH analogs are theoretically 
interesting, especially in dialysis patients with low bone 
turnover but, once again, available data are limited to case 
reports and pilot studies [36]. Lastly, also in the context of 
low bone turnover disease, new anti-sclerostin antibodies 
could be beneficial but until now, only animal studies are 
available [37].
Future Research
Because of the high risk of fracture in dialysis patients, 
there is a clear interest to promote clinical research in the 
field of bone disease. Nephrologists should certainly move 
from an “only bone turnover” (bone quality) point of view 
to a broader vision including the concept of bone quantity. 
This change of concept is necessary because many new and 
potentially useful therapies are now available. However, 
there is still need to clarify the place of DXA, QCT, and 
biomarkers to predict the risk of fractures and/or to evalu-
ate or monitor BMD.
Cardiovascular mortality is the first cause of death in 
dialysis patients. At least in part, vascular calcifications 
explain this cardiovascular over-mortality. The pathophysi-
ology of these vascular calcifications has been suggested to 
share similar pathways with bone physiology. In the future, 
potential connections between bone (and osteoporosis) and 
vessels (and vascular calcifications) will be an interesting 
field of basic and clinical research. Some data suggest an 
inverse correlation between vascular calcifications and 
osteoporosis [20, 27]. Therefore, future studies with osteo-
porosis therapies should be designed with two endpoints; 
the effect on bone (BMD, biomarkers and ideally fracture) 
and the effect on vessels (vascular calcification and ideally 
cardiovascular mortality).
Conclusion
Dialysis status is associated with a major risk of fractures 
compared to the general population. Furthermore, frac-
tures in dialysis patients occur earlier in life and are asso-
ciated with a higher morbidity and mortality. The assess-
ment of bone health and fracture risk in dialysis patients 
may be difficult because of the heterogeneous association 
between (change in) BMD and biomarkers. Moreover, the 
FRAX algorithm does not include dialysis status; DXA is, 
until now, not recommended by KDIGO and bone biopsies 
remain relatively invasive and difficult to interpret. Since 
dialysis status was an exclusion criterion in all large RCTs, 
the role of bisphosphonates is still a subject of debate. 
Denosumab has been shown to be effective but with a 
risk of developing severe hypocalcemia. Teriparatide and 
other PTH analogs may be interesting in dialysis patients 
with low bone turnover, in whom antiresorptives should be 
avoided.
Osteoporosis in Cancer Patients
The term “bone health” in cancer patients encompasses 
the impact of metastatic bone disease and the effects of 
cancer therapy on bone mass and fracture rate. Metastatic 
bone disease is most commonly seen with specific cancer 
types, notably those arising from the breast, prostate, lung, 
and kidney, as well as multiple myeloma. Bone metastases 
weaken the structural integrity of bone, putting patients 
at increased risk of bone complications, skeletal-related 
events (SREs), including pathologic fracture, spinal cord 
compression, or subsequent radiation or surgery to the 
bone. SREs are associated with increased morbidity and 
mortality, decreased quality of life, and increased treatment 
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costs. Many patients with bone metastasis also experience 
bone pain that can be severe and debilitating. Antiresorp-
tive agents markedly reduce the incidence of SREs and 
delay the occurrence of severe bone pain. The reader is 
referred to a recent review for this topic [38]. A second 
connection between cancer and bone is that most drugs 
used to treat hormone-responsive tumors have a deleterious 
indirect effect on bone turnover, BMD, and bone quality. 
In the elderly, cancer treatment-induced bone loss (CTIBL) 
is superimposed on physiological bone loss. This chapter 
focuses on CTIBL in breast cancer and prostate cancer in 
the adjuvant setting. There has been less interest for bone 
health in patients cured from other tumors, although bone 
loss after stem cell transplantation at last received more 
attention.
Breast Cancer
Aromatase inhibitors (AIs) increase overall survival in 
RCTs against tamoxifen and have become the first-line 
hormonotherapy in the adjuvant setting of breast cancer. 
Bone loss is their main side effect. AI therapy is associated 
with an average 2% loss of lumbar spine BMD per year, 
and the effects of AIs on cortical bone and bone strength 
appear to be largely underestimated by classical dual-
energy X-ray absorptiometry (DXA) [39]. Risk of fracture 
is 2–4 times higher in women treated with adjuvant AIs 
than with tamoxifen or placebo [38, 39]. The increased 
risk is independent of the type of AI and, with the excep-
tion of ABCSG-18, the only trial where fracture incidence 
was the primary endpoint, the risk has been underestimated 
because fractures were only reported as adverse events in 
oncology trials. The absolute risk of fracture in women 
treated with AIs ranges from 1–18%. Data from ABCSG-
18 show a fracture rate of 9.6% after 3 years and 26% after 
7 years in the placebo group on AIs only [40].
Published guidelines recommend that women with breast 
cancer receiving an AI or ovarian suppression therapy have 
their bone health monitored for fracture risk, for example, 
with BMD measurement and the FRAX algorithm [38]. 
In FRAX, however, anticancer treatments are not included 
as a unique risk factor and enter in the “secondary osteo-
porosis” group, which underestimates the effect of these 
therapies on fracture risk [38]. As for other conditions 
characterized by an increased fracture rate, patients receiv-
ing AIs should be advised to consume a calcium-enriched 
diet and/or receive calcium supplements, exercise moder-
ately (resistance and weight-bearing exercise), and take 
1000–2000 international units (IU) of vitamin D every-
day. Table 2 summarizes treatment guidelines and possible 
therapeutic schemes with antiresorptives for women on AI. 
Guidance from expert groups for premenopausal women 
with therapy-induced early menopause recommends the 
use of antiresorptives if the BMD Z-score is <2.0 [41]. In 
postmenopausal women, the consensus from expert pan-
els recommends treatment with antiresorptives in patients 
receiving AI therapy with a T-score <2.0 or with two or 
more clinical risk factors for fracture [38].
Data from randomized clinical trials (RCTs) in >5000 
patients show that bisphosphonates and denosumab admin-
istered at doses and schedules that are most often similar 
to those used for postmenopausal osteoporosis can pre-
vent bone loss in women with breast cancer and even lead 
to an increase in BMD [38, 39]. The ABCSG-18 trial, 
which randomized postmenopausal women on AIs to deno-
sumab 60 mg q6m or placebo, found that active treatment 
reduced the risk of first clinical fracture (the primary end-
point) relative to placebo by 50%. Five years following 
randomization, 15% of placebo patients but little over 5% 
of denosumab-treated patients had experienced a fracture. 
A significant protective effect was seen both in women 
with a baseline T-score < -1 and in those with a T-score 
≥ −1 [40]. These new findings will have to be considered 
when updating guidelines for the prevention of AI-induced 
bone loss, especially given that denosumab was not asso-
ciated with additional toxicity. In particular, there was no 
concern over osteonecrosis of the jaw or atypical femoral 
fractures [40]. Important additional evidence for the use of 
antiresorptives in the adjuvant setting is provided by the 
recent Early Breast Cancer Trialists’ Collaborative Group 
(EBCTCG) meta-analysis of data from postmenopausal 
breast cancer patients showing that adjuvant zoledronic 
acid and clodronate could reduce recurrence rate and pro-
long survival. Compelling evidence from this meta-analysis 
of trial data of >18,000 patients supports clinically sig-
nificant benefits of bisphosphonates on the development 
of bone metastases and breast cancer mortality in post-
menopausal women or those receiving ovarian suppression 
therapy [47]. An international panel of experts has recently 
recommended that bisphosphonates, either iv zoledronic 
acid or oral clodronate, are considered as part of the adju-
vant breast cancer treatment in this population. Data from 
the adjuvant use of denosumab in this setting are eagerly 
awaited [44, 48].
Prostate Cancer
Androgen deprivation therapy (ADT) is the cornerstone of 
treatment in prostate cancer but has several adverse effects, 
especially on bone health. ADT can be achieved by cas-
tration, luteinizing hormone-releasing hormone (LHRH) 
agonists or antagonists. Men undergoing ADT should have 
their bone health monitored for fracture risk [49]. As for 
breast cancer, FRAX underestimates the effects of hor-
mone therapy on fracture risk. ADT leads to accelerated 
bone loss and an increase in fracture rate, as evidenced by 
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large retrospective epidemiological studies [50, 51]. Men 
treated with LHRH agonists lose 1–5% of BMD within the 
first year and fracture risk increases with treatment dura-
tion [50]. A matched-cohort study of almost 20,000 men 
found that the risk of fragility fracture (all sites) was 17.2% 
for those on ADT (mean duration 6.5 years) compared 
with 12.7% among men not on ADT (HR 1.65; 95% CI 
1.39–1.54) [51]. Increasing age is an independent risk fac-
tor for fractures, and fracture in prostate cancer more than 
doubles mortality. The recent introduction of the androgen 
synthesis inhibitor abiraterone for castration-resistant pros-
tate cancer (CRPC) could aggravate the problem because of 
its impact on endogenous cortisone production. Abirater-
one must indeed be combined with 10 mg prednisone and 
ADT has to be continued anyway. Abiraterone and other 
new agents significantly extend overall survival in CRPC, 
so that prolonged exposure to steroids and ADT may be 
expected, potentially increasing the risk of osteoporotic 
fracture. Because of its favorable toxicity profile, abirater-
one is especially suited to elderly who are not good candi-
dates for chemotherapy [52].
Table  3 summarizes possible therapeutic schemes with 
antiresorptives for men on ADT. Alendronate, risedronate, 
zoledronic acid, and pamidronate have all been shown to 
prevent BMD loss in patients with locally advanced pros-
tate cancer under ADT [38]. 6–12 monthly zoledronic 
acid and 6-monthly denosumab are most often used. Pros-
tate cancer is essentially a disease of elderly men who are 
more likely than younger men to require dose adjustment 
for renal impairment, which makes denosumab more attrac-
tive than bisphosphonates. Moreover, only denosumab has 
a specific license for ADT-induced bone loss. In a placebo-
controlled trial of denosumab in 1468 men receiving ADT 
for non-metastatic prostate cancer, 3 years of denosumab 
treatment at doses used for the treatment of osteoporo-
sis led to a 62% relative reduction in new vertebral frac-
tures [53]. Although antiresorptive therapies are especially 
important for elderly patients with cancer, they are typi-
cally underutilized in this population and guidelines for this 
indication have received less attention. They should prob-
ably be broadly similar to those in breast cancer and recent 
guidelines advocate that all men aged over 75 years under 
ADT should receive antiresorptive agents at doses used to 
prevent osteoporosis [46]. Underuse of antiresorptive thera-
pies may be more detrimental in elderly compared with 
younger patients because of multiple fracture risk factors, 
including physiological decreases in BMD and increases in 
fracture rate with advancing age.
Hematopoietic Stem Cell Transplantation
Hematopoietic stem cell transplantation (HSCT) is the 
treatment of choice for many patients with malignant and Ta
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non-malignant hematological diseases. Osteoporotic frac-
tures constitute one of the main long-term complications. 
The etiology of bone loss after HSCT is multifactorial, 
including the use of corticosteroids and other immuno-
suppressive drugs, release of inflammatory cytokines, 
and treatment-induced hypogonadism. Even if patients 
undergoing HSCT are most often less than 50 years, the 
incidence of osteopenia and osteoporosis in adults after 
HSCT approaches 50% after 5 years and 20% after 2 years, 
respectively. The degree of bone loss is most often severe, 
especially after allo-HSCT, and cortical bone appears to be 
affected more than trabecular bone [56]. The relative risk 
of fractures is increased seven- to ninefold compared with 
45- to 64-year-old adults in population-based cohort studies 
[57].
All HSCT patients should receive dietary and lifestyle 
advice, including calcium and vitamin D supplementation. 
Menopause hormone therapy (MHT) should be consid-
ered in menopausal women, and testosterone potentially in 
hypogonadal men. Antiresorptives used in this population 
are mostly bisphosphonates but there are few randomized 
trials [58]. The pamidronate trials included the largest 
number of patients and appear to be more representative 
of the real effects of bisphosphonates in this population. A 
randomized study including 99 patients under HSCT with 
or without five 60-mg pamidronate infusions over 1  year 
showed that in the pamidronate group, BMD remained sta-
ble at lumbar spine but still decreased at the femoral neck 
and total hip [59]. In a smaller study, using higher doses 
of pamidronate, comparable to the doses used for the treat-
ment of bone metastases, similar findings were reported 
[60]. There is no reported experience with denosumab in 
patients after HSCT.
Conclusion
To conclude, AIs, ADT, and HSCT are associated with 
bone loss and fracture risk. Therefore, individuals on these 
therapies should have their bone health monitored for frac-
ture risk. The FRAX algorithm, however, does not con-
sider anticancer treatment as a specific risk factor and thus 
underestimates the effect of these therapies. Cancer patients 
treated with AIs, ADT, and HSCT should receive dietary 
and lifestyle advice, including adequate calcium and vita-
min D intake. Furthermore, in patients on AIs and ADT, 
bisphosphonates and denosumab administered at doses 
similar to the treatment of postmenopausal osteoporosis 
can prevent bone loss. Denosumab has also been shown to 
reduce fracture risk in both conditions. Moreover, antire-
sorptives in the adjuvant setting reduce recurrence rate in 
postmenopausal women with breast cancer. The few RCTs 
with bisphosphonates in adults with HSCT showed reduced 
bone loss, while MHT may be considered in menopausal 
women and testosterone in hypogonadal men.
Osteoporosis in Sarcopenic Patients
Sarcopenia corresponds to a progressive and generalized 
loss of muscle mass combined with either loss of muscle 
strength or physical performance [61]. Consequences of 
sarcopenia include physical disability, nursing home admis-
sions, depression, hospitalizations, and mortality, thus an 
increased morbidity and mortality essentially similar to the 
consequences of osteoporosis.
During the last decade, bone and muscle were increas-
ingly recognized as interacting tissues, not only because 
of their adjacent surfaces or as a result of the mechanical 
effects of muscle loading on bone [62]. The “bone-muscle-
unit” is now widely considered as the site of privileged 
exchanges in which the two tissues communicate via par-
acrine and endocrine signals to coordinate their develop-
ment and adapt their response to loading and injury from 
embryologic stages to involution [63, 64]. During growth, 
muscle area seems closely correlated with bone parameters 
such as bone mineral content and femoral circumference. 
Growing evidence suggest that sarcopenia and osteoporo-
sis share many common pathways including the sensitivity 
to reduced anabolic hormone secretion, increased inflam-
matory cytokine activity, anabolic or catabolic molecules 
released by the skeletal muscle or bone cells (i.e., myokines 
and osteokines), and eventually reduced physical activity 
[64, 65].
The concept bone-muscle-unit is evidenced phenotypi-
cally by the observation of a linear relationship between 
BMD and lean body mass at various ages [66]. The mus-
cle–bone cross-talk is also supported by preclinical data, 
showing its presence even before birth in mammals [63]. 
The muscle secretome consists of several hundred secreted 
peptides, providing a whole new paradigm for understand-
ing how muscles communicate with other organs, includ-
ing bones [63]. Several molecules released by muscle affect 
bone, including IGF-1 (insulin-like growth factor-1), fibro-
blast-growth factor-2, interleukin (IL)-6, IL-15, myostatin, 
osteoglycin, FAM5C (family with sequence similarity 5, 
member C), Tmem119 (transmembrane protein 119), iri-
sin, and osteoactivin [63]. However, much less studies were 
dedicated to studying the reverse channel (i.e., from bone 
to muscle). Both osteoblasts and osteocytes were shown to 
secrete cytokines. The effects on muscle of prostaglandin 
E2 and Wnt3A (wingless-type MMTV integration site fam-
ily, member 3A) which are secreted by osteocytes, osteo-
calcin, and IGF-1, produced by osteoblasts, and sclerostin 
secreted by both cell types, are however well documented 
[63].
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With adipose tissue also involved in the complex 
bone–muscle interaction came the suggestion that obesity, 
sarcopenia, and osteoporosis could be concomitantly found 
in a subset of the population, presenting with an entity 
called osteosarcopenic obesity [67]. The mechanism under-
lying this condition is an increase in total and/or abdominal 
adipose tissue that causes an increase in pro-inflammatory 
cytokines as well as some hormonal disturbances leading 
to losses of both muscle and bone. The decrease in muscle 
and bone is associated with a decrease in physical activ-
ity leading to a vicious cycle of progressive loss of muscle 
and bone and a gain in fat [67]. It is likely that these indi-
viduals will present with poorer clinical outcomes caused 
by the cascade of metabolic abnormalities associated with 
the changes in their body composition. This view was sup-
ported by the observation that obese subjects with low 
muscle mass (sarcopenia) or strength (dynapenia) have an 
increased risk of osteoporosis and non-vertebral fracture 
relative to obese alone counterparts. These findings imply 
that sarcopenic and dynapenic obese individuals require 
close monitoring of bone health during ageing.
Bone–muscle Interaction in Clinical Trials
Several studies support the in vivo association of low BMD 
and sarcopenia. In 679 men aged 40–79 years from the 
European Male Ageing Study, sarcopenia was associated 
with low BMD and osteoporosis [68]. Similarly, in 17,891 
subjects from various ethnicities, each standard devia-
tion increase in relative appendicular skeletal muscle mass 
resulted in a 37% reduction in the risk of osteopenia/oste-
oporosis and subjects with sarcopenia were 2 times more 
likely to have osteopenia/osteoporosis [69].
In a study in 591 inpatients, sarcopenia was present in 
64% of women and 95% of men who recently experienced a 
hip fracture [70]. Moreover, sarcopenia was associated with 
lower ability to perform activities of daily living compared 
to presarcopenia. This may reflect an increased risk of post-
hip fracture complications, additional health resources uti-
lization, and higher incidence of contralateral hip fracture. 
In a population of young patients (20–69 years) with a fem-
oral neck fracture, those with low-energy trauma have sig-
nificantly lower femoral neck BMD and fat-free mass than 
those with other trauma mechanisms [71]. These results 
re-emphasize the association between low bone and muscle 
mass in patients with hip fractures, and the need for a com-
prehensive management of these patients.
Furthermore, in Chinese community-dwelling elderly 
aged 65 and older, sarcopenia was a predictor of fracture 
risk independent of BMD and other clinical risk factors, 
and the diagnosis of sarcopenia added incremental value 
to the FRAX algorithm in predicting incident fracture risk 
[72].
Finally, in a cross-sectional study in 680 men and 
women with a mean age of 79 years, sarco-osteoporotic 
individuals were more likely to have a lower MNA (mini-
nutritional assessment) and BMI compared to normal 
elderly [73]. In Italian hip fracture patients, a low intake of 
calories, protein, and leucine was associated with reduced 
muscle mass [74]. This illustrates the importance of detect-
ing nutritional deficits and optimizing nutritional status in 
patients with osteoporosis and sarcopenia in order to pre-
vent poor clinical outcomes such as falls and fractures.
Interventions Targeting both Muscle and Bone
At this stage, no RCTs assessing the concomitant effects 
of a new chemical entity (NCE) on bone and muscle have 
been published. This may be, in part, related to the absence 
of guidelines supporting regulatory studies for NCE to 
manage sarcopenia [75]. However, a better understanding 
of the interconnection of bone and muscle may shift our 
treatment paradigm to “kill two birds with one stone,” i.e., 
to treat sarcopenic patients and prevent fractures, as sug-
gested by Gingis et al. [64].
A potential strategy is to target pathways that centrally 
regulate both bone and muscle (e.g., growth hormone (GH) 
and GH secretagogues, androgens, selective androgen 
receptor modulators, and vitamin D) or to investigate newly 
emerging pathways that might facilitate the communication 
between the two tissues (e.g., activin signaling inhibitors, 
including myostatin-neutralizing antibodies/propeptides, 
recombinant follistatin, follistatin derivatives, and soluble 
activin receptors or myokines) [63, 64]. An overview of 
the results of human clinical studies with these agents has 
recently been published [64].
All authors acknowledge the critical importance of regu-
lar exercise and adequate nutrition to optimize peak bone 
mass and maintain bone and muscle health throughout live 
[63, 67]. In this perspective, two intervention trials are 
worth a comment. Bauer et al. reported, in a well-designed 
13-week RCT, the beneficial effects of a vitamin D- and 
leucine-enriched whey protein oral supplement on mus-
cle mass and lower-extremity function among sarcopenic 
elderly [76]. Knowing the importance of vitamin D and 
proteins for bone health, this nutritional supplement could 
also take place in the armamentarium against osteoporo-
sis [77, 78]. Chahal et  al. investigated the impact of vari-
ous intensities and frequencies of loading doses of physical 
activity on knee extension torque and broadband ultrasound 
attenuation at the heel in middle-aged women. They con-
cluded that physical activity, especially at high intensity 
level and high frequency range, may have beneficial effects 
on muscle strength and bone density in this population 
[79].
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Conclusion
Osteoporosis and sarcopenia are two disorders predomi-
nantly affecting elderly patients and responsible for a major 
clinical and financial burden. Increase in life expectancy 
in most countries and in both sexes makes their diagnosis, 
prevention, and treatment a major social and ethical, yet 
unmet, medical need. Genetic, developmental, paracrine, 
endocrine, and lifestyle factors have dual effects on bone 
mass and muscle mass and function.
The evidence of biochemical and molecular interactions 
between the two tissues needs to be further explored for 
the development of NCE against these twin conditions of 
aging. Targeting pathways that centrally regulate bone and 
muscle or newly pathways that facilitate communication 
between the two tissues are the directions for the identifica-
tion of NCE, which could simultaneously prevent, reduce, 
or restore bone and muscle wasting. It seems wise for 
companies developing such agents to include, within the 
secondary endpoints of their trials, outcomes parameters 
(e.g., DXA, biochemical markers, imaging, quality of life) 
reflecting the effect of these drugs on bone and muscle. 
However, the importance of physical exercise and the need 
for a balanced diet providing sufficient amounts of proteins, 
calcium, vitamin D, and various micronutrients should not 
be underestimated.
Osteoporosis in the Oldest Old
Osteoporosis and Osteoporotic Fractures in Old Age: 
A Challenge
The incidence of osteoporotic fractures increases with age. 
Today, the cumulative incidence of hip fractures in women 
at the age of 80 is close to 30% [80]. Vertebral fractures 
are even more common, with a prevalence of more than 
40% in women older than 80 [81]. Moreover, the burden 
of osteoporosis will only increase in the future because of 
the aging of the population. In Belgium, it is expected that 
the number of osteoporotic fractures will increase with 25% 
in the next 10 years. Osteoporosis in old age is a challenge 
because of its significant burden in terms of morbidity, 
mortality, and economic cost.
Elderly Persons with Osteoporosis are Frail Elderly
According to the World Report on Ageing and Health of 
the World Health Organization (WHO) [82], healthy aging 
is the process of developing and maintaining the functional 
ability that enables well-being in older age. Functional abil-
ity is made up of the intrinsic capacity of the individual 
(the composite of all the physical and mental capacities of 
the individual), relevant environmental characteristics, and 
the interactions between the individual and the environ-
ment. An individual may have reserves of functional ability 
that he or she is not drawing on. These reserves contribute 
to the resilience of the individual. Resilience is the ability 
to maintain or improve a level of functional ability in the 
face of adverse events. Frailty can be considered as the pro-
gressive age-related decline in physiological systems that 
results in decreased reserves of intrinsic capacity, which 
leads to extreme vulnerability to stressors and increases the 
risk of adverse health outcomes [83].
Elderly patients with osteoporotic fractures are not 
“average” elderly, but should be considered as frail persons, 
with a high prevalence of underlying comorbidities and at 
risk of functional deficits [84]. Indeed, in old age, osteopo-
rosis and osteoporotic fractures tend to occur in a particu-
larly frail subset of the population [85]. This frailty will be 
reflected in poor post-fracture outcomes, such as functional 
decline, loss of quality of life, and an increased mortality 
which continues to be observed more than 10 years after 
the fracture [86].
Under‑diagnosis and Under‑Treatment of Osteoporosis 
in Old Age
Despite the increasing evidence for the frequency and 
severity of osteoporosis in the elderly, osteoporosis contin-
ues to be under-diagnosed and under-treated, particularly in 
individuals over the age of 80. This may, at least partly, be 
explained by the fact that evidence of the anti-fracture effi-
cacy of osteoporosis treatment comes mainly from RCTs in 
women with a mean age of 70 to 75 years. Thus, there is an 
urgent need for treatment options with documented efficacy 
in older individuals, not only against vertebral fractures 
but even more so against non-vertebral fractures, as these 
account for most of the morbidity and mortality associated 
with osteoporosis. Treatment options should also be proven 
to be safe in elderly who are frail, with comorbidities and at 
increased risk of adverse events.
Treatment of Osteoporosis in the Oldest Old
In this chapter, the evidence about the efficacy and safety 
of the available osteoporosis therapies in the elderly, and 
especially the oldest old (≥80  year), is discussed. Non-
pharmacological interventions such as fall prevention strat-
egies play an essential role in the treatment of osteoporosis, 
also in elderly, but will not be discussed.
Calcium and Vitamin D Supplementation in old Age
One of the main determinants of bone loss in old age is cal-
cium and vitamin D deficiency and that is why combined 
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calcium and vitamin D supplementation has become one of 
the main components to reduce bone loss and fracture risk 
in old age. Low levels of 25-hydroxyvitamin D (25OHD) 
occur in all age groups; 2–30% of adults in European 
countries have a serum 25OHD level below 10 ng/ml, but 
this may rise to more than 80% in institutionalized elderly 
[87]. In fact, a gradual decline of 25OHD is observed from 
healthy adults over independent elderly to institutionalized 
persons and hip fracture patients [87]. Despite the observa-
tion that the absorption of vitamin  D3 and its metabolism 
into 25OHD and 1,25-dihydroxyvitamin D (1,25(OH)2D) 
is well preserved in elderly without liver or kidney dis-
ease, elderly are at risk of hypovitaminosis D because of 
low vitamin D intake and decreased capacity of the skin to 
produce vitamin  D3 together with less sun exposure [87]. 
Therefore, elderly and especially those in institutions have 
lower levels of 25OHD compared to young individuals. 
Hypovitaminosis D lowers the intestinal calcium absorp-
tion and induces a negative calcium balance, which may be 
enhanced by insufficient calcium intake. This stimulates the 
secretion of PTH, which enhances bone turnover, induces 
osteoporosis and increases fracture risk. Low vitamin D 
may also increase fracture risk by increasing the risk of 
falling apparently through an effect on balance and muscle 
strength [78].
Adequate vitamin D status is therefore essential in the 
prevention of bone loss and osteoporotic fractures. A daily 
intake of 800 IU of vitamin D is recommended for individ-
uals aged ≥ 71 years in order to achieve a serum 25OHD 
level of at least 20 ng/ml as this meets the requirements of 
at least 97.5% of the population [88]. One of the reasons 
why individual RCTs and meta-analyses failed to show a 
reduction in fracture risk with calcium and vitamin D may 
be the lack of targeting of supplementation to persons at 
risk of a negative calcium balance and/or vitamin D defi-
ciency, such as individuals aged ≥ 75 years and institution-
alized elderly. This is illustrated by a recent meta-analysis 
that found that vitamin D with calcium reduced the risk 
of hip fractures in institutionalized but not in community-
dwelling elderly as the latter group is less likely to have 
calcium and/or vitamin D deficiency [89].
Thus, combined supplementation with calcium and vita-
min D is an essential component to reduce bone loss and 
fracture risk in the elderly. However, osteoporosis treat-
ment, on top of calcium and vitamin D, should be consid-
ered in older individuals with osteoporosis and osteoporotic 
fractures.
Pharmacological Osteoporosis Treatment in Old Age
Table 4 gives an overview of the anti-fracture evidence of 
currently approved pharmacological osteoporosis medica-
tion in old age.
Alendronate The efficacy of alendronate as an antiresorp-
tive agent was established by the Fracture Intervention Trial 
(FIT) in postmenopausal women with a prevalent vertebral 
fracture as well as in postmenopausal women with a T-score 
≤ −1.6 at the femoral neck (mean age 70.8 and 67.7 years, 
respectively) [101, 102].
A post hoc analysis of the FIT-trial has evaluated the 
anti-fracture efficacy of alendronate in postmenopausal 
women with the highest fracture risk. This analysis included 
a subgroup with patients aged ≥75 years (range 75–82 
years) [90]. After 3 years, alendronate significantly reduced 
the risk of vertebral fracture by 38% (RR 0.62; 95% CI 
0.41–0.94) in women aged ≥75 years compared to 51% in 
the younger age group (RR 0.49; 95% CI 0.35–0.68). This 
study was followed by another analysis based on pooled 
data from both FIT arms [91]. Focus of this analysis was 
to calculate age-specific fracture rates (55 to <65 years, 65 
to <70 years, 70 to <75 years, and 75–85 years). Relative 
risk reductions for hip (RR 0.47; 95% CI 0.27–0.81) and 
vertebral (RR 0.55; 95% CI 0.37–0.83) fractures were con-
stant among age groups, with an even greater absolute risk 
reduction as age increases. This greater absolute risk reduc-
tion was explained by the age-related increase in fracture 
risk in the placebo group. Finally, also a very recent study 
showed that alendronate in patients older than 80 years who 
had a prior fracture was associated with a reduced hip frac-
ture risk (HR 0.72; 95% CI 0.61–0.85) [92]. The reduction 
in hip fracture risk was maintained across all age quartiles 
and the absolute risk reduction at 5 years increased sub-
stantially by quartile of age. Moreover, adverse events were 
not more common in the higher age quartiles.
Risedronate In 1999 and 2000, the VERT-trials demon-
strated the efficacy of risedronate to prevent vertebral and 
non-vertebral fractures in postmenopausal women (mean 
age approximately 70 years) [103, 104]. In 2001, the effect 
on hip fracture risk was examined in the HIP-trial, of which 
one arm included postmenopausal women with a mean age 
of 74 years [93].
The other arm of the HIP-trial included 3886 women 
aged ≥80 years with a low femoral neck BMD or at least 
one non-skeletal risk factor for hip fracture (e.g., poor gait 
or a propensity to fall) [93]. After 3 years, no reduction in 
hip fracture risk was observed. Of note, the majority of the 
participants was selected based on non-skeletal risk factors 
[93]. A second analysis was a pooled analysis of the VERT-
and HIP-trials in 1392 women with osteoporosis aged ≥80 
years [94]. After 3 years, the risk of vertebral fractures 
was reduced by 44% (HR 0.56; 95% CI 0.39–0.81). The 
incidence of non-vertebral fractures was not significantly 
different.
The difference in benefit for vertebral versus non-verte-
bral fractures in the elderly might be explained by the fact 
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Table 4  Relative risk (95% CI) of new vertebral, hip and non-vertebral fractures compared with placebo in very elderly women receiving cur-
rently available osteoporosis treatments
RCT Included 
participants
N Mean age 
(years)
Vertebral fractures Hip fractures Non-vertebral 
fractures
Alendronate Post hoc 
analysis FIT 
Vertebral 
Fracture 
Arm (3 
years) [90]
Women aged 
75–82 years
539 Not speci-
fied
RR 0.62
95% CI 0.41–0.94
p < 0.05
pinteract < 75 & ≥ 75 years 
NS
– –
Pooled 
analysis FIT 
Vertebral 
and Clinical 
Fracture 
Arm with 
low BMD 
(3–4 years) 
[91]
Women aged 
55–80 years
55- < 65 
years
65- < 70 
years
70- < 75 
years
75–85 years
3658 RR 0.55
95% CI 0.37–0.83
(constant RR)
RR 0.47
95% CI 0.27–0.81
(constant RR)
–
Axelsson 
et al. [92]
(5 years)
Women aged 
71.1–92.3 
years with 
a prior 
fracture
110,190 82.4 Years – HR 0.72
95% CI 0.61–0.85
p < 0.001
–
Risedronate HIP - arm 2 
(3 years) 
[93]
Women 
aged ≥ 80 
years
with at least 
one non-
skeletal risk 
factor for 
hip fracture
or T-score at 
FN ≤4 or 
≤3 + hip 
axis 
length of 
≥ 11.1 cm
3886 83 Years – RR = 0.8
95% CI 0.6–1.2
p = 0.35
10.8% (Risedronate) 
versus 11.9% (pla-
cebo); p = 0.43
Post hoc 
pooled 
analysis 
VERT-NA, 
VERT-MN 
and HIP (3 
years) [94]
Women 
aged ≥ 80 y 
with T-score 
≤2.5 at 
FN or at 
least one 
prevalent 
vertebral 
fracture
1392 83 years HR 0.56
95% CI 0.39–0.81
p = 0.003
p interact < 80 & ≥ 85 years 
NS
– 14.0% (Risedronate) 
versus 16.2% 
(placebo)
p = 0.66
Zoledronic 
acid
Post hoc 
analysis
HORIZON-
PFT and 
RFT (3 
years) [95]
Women 
aged ≥ 75 
years with 
T-score ≤ 
−2.5 at FN 
or ≥ 1 ver-
tebral or hip 
fracture
3888 79.4 years HR 0.34
95% CI 0.21–0.55
p < 0.001
pinteract < 75 & ≥ 75 years 
NS
HR 0.82
95% CI 0.56–1.2
p = 0.297
pinteract < 70 & ≥ 75 years 
SS
HR 0.73
95% CI 0.60–0.90
p = 0.002
pinteract < 70 & ≥ 75 years 
NS
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that bisphosphonates impact on BMD, illustrated by the 
significant reduction of vertebral fractures. Bisphospho-
nates, however, do not impact on non-skeletal risk factors 
of fractures such as gait disturbances, impaired balance, 
and fall risk. These non-skeletal factors are of particular 
importance in the occurrence of non-vertebral fractures in 
the elderly, as they are more prone to falling. In contrast, 
vertebral fractures are often atraumatic, thus less influenced 
by non-skeletal risk factors. An additional explanation for 
this discrepancy between the older and younger population 
in preventing non-vertebral fractures, might be insufficient 
statistical power in the older age group.
Ibandronate No data are available on the anti-fracture effi-
cacy of ibandronate in the very elderly.
Zoledronic Acid The HORIZON Pivotal Fracture Trial 
(HORIZON-PFT) showed that zoledronic acid is an effec-
tive therapy in postmenopausal women (mean age 73 years), 
with a reduction in the risk of vertebral, hip, and non-ver-
tebral fractures [105]. In the HORIZON-Recurrent Fracture 
Trial (HORIZON-RFT), zoledronic acid reduced the risk of 
new vertebral and non-vertebral fractures in patients with a 
hip fracture (mean age 74.4 years) [106].
In 2010, a post hoc pooled analysis of both HORIZON 
trials that focused on women aged ≥ 75 years with osteo-
porosis was published (mean age 79.4 years) [95]. After 
3 years, the incidence of vertebral and non-vertebral frac-
ture was significantly lower in the treated group compared 
to the placebo group (HR 0.34; 95% CI 0.21–0.55 and HR 
0.73; 95% CI 0.6–0.9, respectively). The benefit was com-
parable with the risk reduction in subjects <75 years in 
HORIZON-PFT and HORIZON-RFT. However, contrary 
to younger persons, the reduction in hip fracture risk did 
not meet statistical significance in patients ≥75 years. As 
mentioned above, possibly the sample size was not pow-
ered to detect hip fracture risk reduction in the older age 
group. Another explanation is the greater influence of non-
skeletal risk factors for hip fractures with increasing age.
Denosumab In women with a mean age of 72.3 years, den-
osumab has been established as a safe and effective therapy 
Results in bold indicate significant results
FN femoral neck, LS lumbar spine, y years, ITT intention to treat, NS not significant
Table 4  (continued)
RCT Included 
participants
N Mean age 
(years)
Vertebral fractures Hip fractures Non-vertebral 
fractures
Denosumab Post hoc 
analysis
FREEDOM 
(3 years) 
[96]
Women 
aged ≥ 75 
years
2471 78.2 years – 0.9% (denosumab) 
versus 2.3% (pla‑
cebo)
p < 0.01; ARR 1.4%
pinteract < 75 & ≥ 75 years 
NS
–
Preplanned 
analysis 
FREEDOM 
(3 years) 
[97]
Women 
aged ≥ 75 
years
2471 78.2 RR 0.36
95% CI 0.25–0.53
pinteract < 75 & ≥ 75 years 
NS
– RR 0.84
95% CI 0.63–1.12
p interact < 75 & ≥ 75 years 
NS
Strontium 
ranelate
Preplanned 
pooled 
analysis 
SOTI and 
TROPOS (3 
years) [98]
Women aged 
80–100 
years
1488 83.5 years RR 0.68
95% CI 0.50–0.92
p = 0.013
RR 0.68
95% CI 0.42–1.10
p = 0.112
(not powered)
RR 0.69
95% CI 0.52–0.92
p = 0.011
Preplanned 
pooled 
analysis 
SOTI and 
TROPOS (5 
years) [99]
Women aged 
80–100 
years
1489 83.5 years RR 0.69
95% CI 0.52–0.92
RR 0.76
95% CI 0.50–1.15
(not powered)
RR 0.73
95% CI 0.57–0.95
Teriparatide Prespecified 
subgroup 
analysis 
FPT (19 
months) 
[100]
Women 
aged ≥ 75 
years
244 78.3 years RR 0.35
p < 0.05
p interact < 75 & ≥ 75 years 
NS
– RR 0.75; p = 0.661
(not powered)
p interact < 75 & ≥ 75 years 
NS
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by the FREEDOM trial, with a significant risk reduction of 
vertebral, hip and non-vertebral fractures [107].
A post hoc analysis of FREEDOM was carried out in 
2011 to evaluate the effect of denosumab in persons aged 
≥75 years [96]. In this group (mean age 78.2 years), den-
osumab significantly reduced the risk of hip fractures by 
62%, comparable with the risk reduction in the overall 
FREEDOM study population. Moreover, no significant 
difference in adverse events was observed in the older sub-
group [96]. In 2012, another analysis of FREEDOM con-
firmed that denosumab reduces the risk of vertebral and 
non-vertebral fractures in subjects older than 75 years (RR 
0.36; 95%CI 0.25–0.53 and RR 0.84; 95% CI 0.63–1.12, 
respectively) to the same extent as in younger subjects (RR 
0.30; 95% CI 0.22–0.41 and RR 0.78; 95% CI 0.63–0.96) 
[97]. Moreover, treatment safety and efficacy of denosumab 
are not affected by renal function, so elderly with renal 
impairment will experience the same anti-fracture efficacy 
as patients with normal renal function [108]. However, 
since the use of denosumab is associated with a high rate of 
severe hypocalcemia in patients with advanced CKD, close 
monitoring and replacement of calcium and vitamin D is 
required to avoid the development of hypocalcemia in these 
patients.
Thus, denosumab is an effective therapy to prevent ver-
tebral, non-vertebral, and hip fractures in the elderly, in 
contrast to bisphosphonates with no significant reduction 
in hip fracture risk by risedronate and zoledronic acid. 
As mentioned, this might be explained by lack of statisti-
cal power. However, it is tempting to speculate that this 
observation is due to the mechanism of denosumab, differ-
ent from that of bisphosphonates, with distinct effects on 
cortical bone. Cortical porosity is indeed one of the main 
determinants of non-vertebral fracture risk, including hip 
fracture risk.
Strontium Ranelate The anti-fracture efficacy of strontium 
ranelate was established by two trials, SOTI and TROPOS, 
in women with a mean age of 69.3 and 76.7 years, respec-
tively [109, 110].
A preplanned pooled analysis of both trials was under-
taken to confirm these results in patients older than 80 
years [99]. After 5 years, the risk of vertebral and non-
vertebral fractures was reduced by 31% (RR 0.69; 95%CI 
0.52–0.92) and 27% (RR 0.73; 95%CI 0.57–0.95), respec-
tively [99]. The numbers needed to treat were lower in 
women aged ≥ 80 years than in younger women. This is 
because a similar relative risk reduction in both age groups 
will avert more fractures in the older age group which has 
a higher baseline fracture risk [98]. Statistical significance 
for hip fracture risk reduction was not reached, but the 
analyses were not designed to quantify the reduction in hip 
fracture risk.
Thus, these analyses showed a significant reduction in 
the risk of vertebral and non-vertebral fractures in persons 
aged ≥ 80 years treated with strontium ranelate. However, 
the finding of an increased risk of cardiac events, including 
myocardial infarction, in addition to the already recognized 
risk of venous thromboembolism, has limited its use in 
clinical practice, although it remains a useful alternative in 
elderly with severe osteoporosis, unable to take other treat-
ment and without cardiovascular contraindications [111].
Anabolic Therapy Daily injections of teriparatide reduce 
the risk of vertebral and non-vertebral fractures, as shown 
in the Fracture Prevention Trial (FPT) in women (mean age 
69.5 years) with a prior vertebral fracture [112].
A prespecified subgroup analysis of the FPT-study was 
undertaken in 2006 to investigate the effect of teriparatide 
in persons aged 75 years and older (mean age 78.3 years) 
[100]. In this subgroup, 5.2% in the teriparatide group and 
15.1% in the placebo group had a new vertebral fracture 
after 19 months. Treatment-by-age interaction was not sig-
nificant, indicating that the effect of teriparatide was not 
statistically different in younger and older patients. Also 
for non-vertebral fractures, the treatment-by-age interaction 
was not significant. There was no significant difference in 
the safety profile between younger and older participants. 
So, age does not affect the safety and efficacy of teripara-
tide in preventing fractures. The major disadvantage, how-
ever, is the daily subcutaneous administration which may 
be a burden for elderly.
Also for abaloparatide, a novel 34-amino acid PTH-
related peptide (PTHrP) which significantly reduced the 
risk of new vertebral and non-vertebral fractures in the 
Abaloparatide Comparator Trial in Vertebral Endpoints 
(ACTIVE), there was a consistent fracture risk reduction 
across different age groups (<65 vs. 65 to <75 vs. ≥75 
years) [113].
Conclusion
In old age, osteoporosis and osteoporotic fractures tend to 
occur in a particularly frail subset of the population. Treat-
ment of osteoporosis is of particular concern in the elderly 
because of the substantial burden of osteoporotic fractures 
in terms of morbidity, mortality, and economic cost. Cal-
cium and vitamin D is an essential component in the man-
agement of osteoporosis in old age. Adding osteoporosis 
treatment reduces the risk of fractures even more, at least in 
older individuals with documented osteoporosis and at least 
for vertebral fractures and maybe also for hip fractures. In 
frail elderly with documented osteoporosis, treatment may 
even be more effective than in younger patients.
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General Conclusions
In this consensus paper, we reviewed the evidence about 
the evaluation and management of osteoporosis in frail 
persons. This is of particular concern because of the 
major burden of osteoporotic fractures in terms of mor-
bidity and mortality in frail individuals such as patients 
with AN, dialysis and cancer patients, persons with sar-
copenia, and the oldest old.
AIs, ADT, and HSCT in cancer patients are associated 
with increased bone loss and fracture risk, as are dialy-
sis status, old age, and AN. Sarcopenia is also associated 
with low BMD. Low muscle and bone mass results in a 
decrease in physical activity, ultimately leading to osteo-
sarcopenic obesity.
Therefore, individuals treated with AIs, ADT, and 
HSCT, as well as elderly and/or sarcopenic individu-
als and patients with AN should have their bone health 
monitored for fracture risk with DXA. Until recently, 
DXA was not recommended in dialysis patients, but this 
may change in future as recent data suggest that DXA 
may also predict fractures and maybe even mortality in 
dialysis patients. In the FRAX algorithm, age and BMI, 
but not anticancer treatments, dialysis status, and sarco-
penia are considered as specific risk factors. Therefore, 
the effect of these later conditions on fracture risk may be 
underestimated by this algorithm.
In all these frail individuals, a healthy lifestyle should 
be recommended, consisting of physical exercise (except 
in AN), adequate calcium and vitamin D intake, and cer-
tainly in persons with AN and osteosarcopenic obesity, 
recovering a normal BMI. Furthermore, in patients on 
AI and ADT, bisphosphonates and denosumab adminis-
tered at doses similar to the treatment of postmenopausal 
osteoporosis are recommended to prevent bone loss and 
reduce fracture risk. After HSCT, also testosterone may 
be considered in hypogonadal men and MHT in meno-
pausal women. AN adolescents may also be treated with 
MHT, while antiresorptives and/or anabolics are only 
indicated in adults, not adolescents, with AN. Similarly, 
in elderly, antiresorptive and/or anabolic treatment is 
indicated to prevent osteoporotic fractures. As compared 
to younger individuals, elderly have a higher absolute 
risk reduction because of their higher baseline fracture 
risk. In dialysis patients, there are few studies, although 
some data suggest a positive effect of bisphosphonates, in 
lower dosages than used in the general population, and of 
denosumab which is, however, associated with a higher 
risk of severe hypocalcemia. Antiresorptives should be 
avoided in dialysis patients with low bone turnover, in 
whom teriparatide may be of theoretical interest. Finally, 
more research is needed to develop pharmacological ther-
apies that have a concomitant effect on muscle and bone.
To conclude, frail individuals are at risk of bone loss 
and fractures. Therefore, in these patients, it is advised 
to regularly monitor bone health by DXA or, if available, 
other techniques such as QCT. FRAX may not always ade-
quately predict fracture risk. Strategies to prevent bone loss 
and fractures include advising a healthy lifestyle as well as 
initiating specific osteoporosis therapy. Further research is 
needed to determine the role of new osteoporosis medica-
tion in frail individuals as well to develop medication that 
target not only bone, but also concomitant affected systems 
such as muscles and the cardiovascular system.
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